Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
SPRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $0.87
Previous CloseN/A
Volume285.87K
Average Volume (3M)270.67K
Market Cap
$12.09M
Enterprise Value-$37.21M
Total Cash (Recent Filing)-$4.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 07, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,302,600
10 Day Avg. Volume239,412
30 Day Avg. Volume270,668
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.96
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-3.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda0.95
Forecast
1Y Price Target
$1.25Price Target Upside331.03% Upside
Rating ConsensusHold
Number of Analyst Covering0
---
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Delays Annual Report Filing
PremiumCompany Announcements
Spruce Biosciences Appoints Interim Chief Medical Officer
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySpruce Biosciences ended 3Q24 with $60.1M in cash and cash equivalents, which is expected to be sufficient to fund operations at least into 2026.
Market PotentialThe CAH opportunity is considered large with approximately 20,000-30,000 patients in the U.S. and around 250 new patients identified via newborn screening annually.
Partnership OpportunitiesSPRB entered a low-risk partnership with HMNC Brain Health to run a Phase 2 proof-of-concept trial of tildacerfont in major depressive disorder.
Bears Say
Clinical Trial ResultsTildacerfont endocrine clinical readouts disappoint—now in holding pattern.
Regulatory ChallengesTildacerfont faces an uncertain future at best, particularly in the wake of the recent U.S. regulatory approval of crinecerfont.
Stock PerformanceShares of Spruce Biosciences were trading at approximately 37% of end-quarter cash before the news, and were down around 22% in the aftermarket.
---
Ownership Overview
19.78% Insiders
2.67% Mutual Funds
19.52% Other Institutional Investors
56.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.26 and its highest was $0.87 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $12.09M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is May 07, 2025 which is in 32 days.
How were Spruce Biosciences’s earnings last quarter?
Currently, no data Available
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -0.21.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,302,600 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.
---
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
---
SPRB Stock 12 Month Forecast
Average Price Target
$1.25
▲(331.03% Upside)
Technical Analysis
---